Clinical Trial Update: Cell Therapy by Bone Marrow-derived Mononuclear Cells (BMC) for Large Bone Defect Repair: Phase-I Clinical Trial [Phase 1]

View source ↗

Summary

Phase I clinical trial using bone marrow-derived mononuclear cells to repair large bone defects, completed in proximal humerus fracture patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Defect
• Fracture of Proximal Humerus

Drugs mentioned

• Bone marrow-derived mononuclear cell (BMC) therapy (bone marrow-derived mononuclear cells)

Snippet

Sponsor: Goethe University | Conditions: Humerus Fracture Displaced Proximal | Phase 1 | Status: COMPLETED